Using low-dose chemotherapy with controlled blood sugar to treat advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of low-dose chemotherapy administered under hypoglycemic conditions to treat patients with relapsed refractory advanced solid tumors. By managing blood sugar levels, the approach aims to enhance the immune response against tumor cells while minimizing the cytotoxic effects typically associated with chemotherapy. Patients will receive treatment at Wuxi People's Hospital, where their progress will be monitored based on measurable tumor lesions. The study focuses on patients who have not responded to standard therapies and have specific eligibility criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female aged 18-75 years;
2. ASubjects must have histologically- or cytologically-confirmed diagnosis of advanced solid tumor(s) and have progressed on or is not eligible for available standard therapy;
3. Subjects have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (non-nodal lesions with longest diameter ≥ 10 mm, or nodal lesions with short diameter ≥ 15 mm);
4. ECOG score of 0-2, lifespan \> 12 weeks;
5. Women of childbearing age who have a negative pregnancy test within 7 days before treatment. Female patients of childbearing age, and male patients with partners of childbearing age must agree to use at least one medically recognized contraceptive method during study treatment and within at least 6 months after the last dose of investigational drug;
6. Voluntarily participated in this study, signed the informed consent form, had good compliance, and cooperated with the follow-up

Exclusion Criteria:

1. The patient is diagnosed with central nervous system leukemia(symptoms, signs, imaging, cerebrospinal fluid);
2. White blood cell count ≥ 50×10\^9/ L or patients with rapid disease progression can't be guaranteed to complete a full treatment cycle;
3. Patients with fungal, bacterial, viral or other uncontrollable infections or requiring four-level isolation treatment.
4. HIV, HBV and HCV positive;
5. Patients with diseases of the central nervous system or autoimmune central nervous system lesions, Including stroke, epilepsy, dementia;
6. Patients have myocardial infection, cardiac angiography or stents, active angina or other obvious clinical symptoms, or have cardiopathic asthma or cardiovascular lymphocytic infiltrates，within 12 months;
7. Patients are on anticoagulation or have severe coagulopathy (APTT\>70);
8. Patients in any condition requiring systemic treatment with corticosteroids or other immunosuppressive agents within 2weeks prior to investigational drug administration;
9. Patients were infected with covid-19 within 2weeks prior to investigational drug administration;
10. Subjects having any serious uncontrolled disease or in other conditions that would preclude them from receiving study treatment and are considered unsuitable for this study in the opinion of the investigator;
11. Subjects in other conditions that are considered unsuitable for this study by the investigator.-

Where it's running

• Wuxi People's Hospital
  Wuxi, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Peihua Lu
• Email: 13625653@qq.com
• Phone: 0510-85350835

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ABSK141 for advanced solid tumors with KRAS G12D mutation

  This trial tests an oral drug called ABSK141 to see if it is safe and helps adults with advanced solid tumors that have a KRAS G12D mutation.

  Recruiting Phase 1/2 Abbisko Therapeutics Co, Ltd · Shanghai · NCT07417189

• HMPL-A580 for adults with advanced or metastatic solid tumors

  This tests whether HMPL-A580 is safe and might help adults with unresectable advanced or metastatic solid tumors.

  Recruiting at 9 sites Phase 1/2 Hutchmed · Orange, California and 13 other locations · NCT07396584

• GC203 TIL therapy for advanced solid tumors in adults

  This trial tests GC203 tumor-infiltrating lymphocyte therapy in adults with solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 Shanghai Juncell Therapeutics · Shenzhen · NCT07256756

• HMPL-A251 for adults with advanced or metastatic HER2-expressing solid tumors

  This trial will test a new drug called HMPL-A251 to see if it is safe and helps adults with unresectable or metastatic HER2-expressing solid tumors.

  Recruiting at 11 sites Phase 1/2 Hutchmed · Denver, Colorado and 14 other locations · NCT07228247

• PANK-003 cell injection with chemotherapy for solid tumors

  This study is testing if PANK-003 cell injections combined with chemotherapy can help people who have had surgery for solid tumors like lung or breast cancer feel better and improve their chances of recovery.

  Recruiting Phase 1 Shenzhen Celconta Life Science Co., Ltd. · Anyang, Henan · NCT06897228

• Evaluating DCR-PDL1 for adults with solid tumors

  This study is testing a new treatment called DCR-PDL1 given through an IV to see if it's safe and works for adults with solid tumors.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Irving, Texas and 1 other locations · NCT06504368

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.